Outlook Therapeutics (OTLK) Rises Dramatically Following FDA Approval of Lytenava
OTLK's stock jumps after FDA approval of Lytenava, with analysts projecting nearly 300% upside ahead of its launch.
Capricor Therapeutics (CAPR) Faces Devastating Losses Following FDA Concerns
Capricor Therapeutics suffers a staggering 67% drop as FDA concerns about Deramiocel loom large, dividing analysts on approval prospects.
SNDL Inc. Expands U.S. Footprint with Acquisition of Parallel Assets: What It Means for Investors
SNDL's acquisition of Parallel positions it strategically in the U.S. cannabis market, signaling potential growth and investor opportunities…
Outlook Therapeutics (OTLK) Stock Soars After FDA Approval: What Investors Should Know
Outlook Therapeutics shares rise after FDA approval of LYTENAVA, with a significant analyst upgrade and potential for market impact.
Capricor Therapeutics (CAPR): A Cautionary Tale for Biotech Investors Following 67% Drop
Capricor Therapeutics plummets 67% amid FDA concerns, highlighting the high-stakes nature of biotech investments.
Capricor Therapeutics Faces Critical FDA Review: What’s Next for CAPR Investors?
Capricor Therapeutics navigates a critical FDA review, impacting stock dynamics and future growth potential.
OTLK Stock Soars After FDA Approval: What Investors Need to Know
Outlook Therapeutics' FDA approval for its wet AMD drug could signal a significant opportunity for investors in OTLK stock.
Pfizer's Talzenna-Xtandi Filing: A Potential Game Changer in Prostate Cancer Treatment
Pfizer's Talzenna and Xtandi filing could reshape prostate cancer treatment, signaling a strategic expansion in oncology.
BridgeBio Pharma's NDA for Encaleret: A Significant Milestone for Investors
BridgeBio Pharma's NDA acceptance for encaleret marks a pivotal moment for investors, highlighting potential commercialization timelines.
Hims & Hers Stock Surges After FDA Advisory Panel Backs Peptide Compounding
Hims & Hers stock saw a 13% increase following a favorable FDA panel vote on peptide compounding, raising investor optimism.
Outlook Therapeutics: Anticipating a Critical FDA Decision on Lytenava
Investors are closely watching Outlook Therapeutics as the FDA decision on Lytenava for wet AMD approaches, following two previous rejection…
Pfizer's Talzenna-Xtandi Combo: A Game Changer for Prostate Cancer Treatment?
Pfizer's recent FDA approval for Talzenna and Xtandi's combination therapy could reshape prostate cancer treatment and influence its dividen…